Analytical Data
-
Gene name
HLA-B*15:01&B2M Monomer
- Application
-
Alternative Names
HLA-B*1501 & B2M
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
SCQ83648.1 (G25-V309)&P61769
-
Expression Region
SCQ83648.1 (G25-V309)&P61769 (I21-M119)
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-B*15:01 is a specific allele of the human leukocyte antigen (HLA) class I gene, which plays a crucial role in the immune system by presenting peptide antigens to CD8+ T cells. Its association with various diseases, particularly its link to drug hypersensitivity reactions, has made it a focal point of immunogenetic research. B2M (beta-2-microglobulin) is a component of the HLA class I molecule and is essential for its stability and surface expression. The study of HLA-B*15:01 and B2M monomeric recombinant proteins aims to enhance our understanding of HLA antigen presentation and its implications in disease susceptibility and immune response. By producing these recombinant proteins, researchers can investigate their structural and functional properties, assess how specific peptides are bound and presented, and explore the mechanistic pathways of T cell activation. This research holds potential significance for developing innovative therapeutic strategies, including personalized medicine approaches for patients at risk of HLA-associated drug reactions or other immune-mediated disorders. Overall, the investigation into HLA-B*15:01 and B2M monomer recombinant proteins contributes to a deeper understanding of the immunological landscape, which is critical for advancing treatments in a range of autoimmune, infectious, and allergic diseases.
